Press Release: European Medicines Agency recommends authorisation of first medicine specifically for irritable bowel syndrome

Author (Corporate)
Series Title
Series Details EMA/CHMP/611096/2012 (21.9.12)
Publication Date 21/09/2012
Content Type

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), on 21 September 2012, recommended the authorisation of the first medicine specifically for the symptomatic treatment of irritable bowel syndrome (IBS) in the European Union (EU).

The Agency recommended that Constella (linaclotide) be authorised for adults with moderate to severe IBS with constipation (IBS-C), a common subtype of the disease.

Source Link Link to Main Source http://www.emea.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/09/news_detail_001611.jsp&mid=WC0b01ac058004d5c1
Related Links
EMA: Press Release: EMA/CHMP/611096/2012 (21.9.12) http://www.emea.europa.eu/docs/en_GB/document_library/Press_release/2012/09/WC500132887.pdf

Subject Categories
Countries / Regions